Vertex Pharmaceuticals

Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Flag link:
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
gene editing
Flag link:
Vertex hits a biomarker bump on road to new drug
Vertex hits a biomarker bump on road to new drug
Biopharma Dive
Vertex Pharmaceuticals
AAT
VX-814
Flag link:
Vertex deal for Scotland — no deal for England
Vertex deal for Scotland — no deal for England
Endpoints
Vertex Pharmaceuticals
cystic fibrosis
Scotland
England
UK
Symkevi
Orkambi
Flag link:
Don’t Blink or You’ll Miss Vertex’s Next Move, And It’s Bound to Be a Good One
Don’t Blink or You’ll Miss Vertex’s Next Move, And It’s Bound to Be a Good One
Motley Fool
Vertex Pharmaceuticals
Flag link:
Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes
Vertex’s next act: a billion-dollar bet on a cure for type 1 diabetes
Stat
Vertex Pharmaceuticals
M&A
diabetes
type 1 diabetes
Semma Therapeutics
Flag link:
Vertex sinks on reports of patient deaths tied to cystic fibrosis drug
Vertex sinks on reports of patient deaths tied to cystic fibrosis drug
Stat
Vertex Pharmaceuticals
cystic fibrosis
patient deaths
Symdeko
Flag link:
FDA decision on Vertex's CF triple will come just ahead of planned CEO shakeup
FDA decision on Vertex's CF triple will come just ahead of planned CEO shakeup
Endpoints
Vertex Pharmaceuticals
FDA
cystic fibrosis
VX-445
tezacaftor/ivacaftor
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
As negotiations with England labor on, Scotland rejects routine use of Vertex's cystic fibrosis drugs
As negotiations with England labor on, Scotland rejects routine use of Vertex's cystic fibrosis drugs
Endpoints
Vertex Pharmaceuticals
UK
Scotland
cystic fibrosis
Flag link:
Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
Translate Bio
MRT5005
Flag link:
Vertex expects more, perhaps bigger M&A to come
Vertex expects more, perhaps bigger M&A to come
Biopharma Dive
Vertex Pharmaceuticals
M&A
Flag link:
Vertex’s CF ‘firepower’ to fund more deals, broader pipeline
Vertex’s CF ‘firepower’ to fund more deals, broader pipeline
BioCentury
Vertex Pharmaceuticals
cystic fibrosis
Flag link:
Vertex's planned CEO handoff could signal stagnant growth to come: analyst
Vertex's planned CEO handoff could signal stagnant growth to come: analyst
Fierce Pharma
Vertex Pharmaceuticals
Jeff Leiden
Reshma Kewalramani
Pharma CEOs
Flag link:
Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO
Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO
Stat
Vertex Pharmaceuticals
Pharma CEOs
Reshma Kewalramani
Jeffrey Leiden
Flag link:
Vertex files cystic fibrosis triple therapy with FDA
Vertex files cystic fibrosis triple therapy with FDA
PM Live
Vertex Pharmaceuticals
FDA
cystic fibrosis
VX-445
Flag link:
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
The Week Ahead In Biotech: Pending Clinical Readouts In Focus
Yahoo/Benzinga
Retrophin
Karyopharm
Celyad
uniQure
Sangamo Therapeutics
Catalyst Biosciences
Novo Nordisk
Reata Pharmaceuticals
Vertex Pharmaceuticals
Bellicum
Gilead Sciences
Jaguar Health
TRACON Pharmaceuticals
FibroGen
Aslan Pharma
ObsEva
Sorrento Therapeutics
Flag link:
3 Big Biotechs Hold Growth Potential in Second Half of 2019
3 Big Biotechs Hold Growth Potential in Second Half of 2019
Yahoo/Zacks.com
Alexion
Gilead Sciences
Vertex Pharmaceuticals
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:

Pages